Biocept introduces blood-based test for detection, monitoring of prostate cancer and

[News]

Biocept, Inc., a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient's blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

More... (http://www.news-medical.net/news/20160107/Biocept-introduces-blood-based-test-for-detection-monitoring-of-prostate-cancer-and-breast-cancer.aspx)